• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
How AI + HI Are Transforming Vaccine Development (and Why We’re Grateful for You)

How AI + HI Are Transforming Vaccine Development (and Why We’re Grateful for You)

by Elena Iemma | Nov 13, 2023 | Blog

This is a two-way street Hey Hey, Hallo, Hola, Ciao, Namaste, Hello, Bonjour, Konnichiwa! When do you do your “thinking” about the day? Do you do it while running? I do! And lately, I’ve been thinking about AI and Human Intelligence in vaccine development—how far...
AI Meets Animal Health: Smarter Vaccine Design with EpiCC™ and Human Insight

AI Meets Animal Health: Smarter Vaccine Design with EpiCC™ and Human Insight

by Elena Iemma | May 24, 2023 | Blog

AI Meets Animal Health: Smarter Vaccine Design with EpiCC™ and Human Insight The future of animal health is being shaped by powerful new technologies. At EpiVax, we’re applying AI in animal vaccine design to improve T cell epitope coverage, strengthen immune...
ISV 2022 Computational Vaccinology Pre-Conference Workshop September 17th, 2022 ***Updated with Pictures******

ISV 2022 Computational Vaccinology Pre-Conference Workshop September 17th, 2022 ***Updated with Pictures******

by Elena Iemma | Jul 22, 2022 | Events

A big thank you to everyone that came out to the pre-conference Computational Vaccinology workshop at ISV! Agenda and pictures from the day below. ISV 2022 Computational Vaccinology Conference Workshop Saturday September 17, 9-4 pm ET Delta Hotels Québec 690 Boul René...
2021 International Society for Vaccines (ISV) Annual Virtual Congress

2021 International Society for Vaccines (ISV) Annual Virtual Congress

by Elena Iemma | Sep 10, 2021 | Events

EpiVax participated in the  2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021. The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community. Multiple EpiVax...
EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

by Elena Iemma | May 17, 2021 | News

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}